Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Does Cinnamon Help with Weight Loss?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

How Does Semaglutide Work to Lose Weight?

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Mental Health Disorders, Weight Gain, and Exercise

Semaglutide and Weight Loss in Menopause

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Circadian Rhythm and Weight Loss

Weight Loss After Bariatric Surgery

Cachexia and Cancer

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

See more featured articles »

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Cachexia / Wasting Syndrome

The Natural Molecule That Could Rival Ozempic

Wegovy: A Breakthrough in Weight Loss?

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Unexplained Weight Loss: When It Might Signal a Health Problem

Vegetarian Diets for Weight Loss

Military Diet: Health Risks

How Oral GLP-1 Drugs Work For Weight Loss

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Latest Weight Loss News and Research

HonorHealth Research Institute tests steam therapy for diabetes treatment

HonorHealth Research Institute is looking to become the first research facility in the nation to begin a new clinical trial that aims to modify the lining of the digestive tract with the use of steam energy to control type II diabetes without the use of drugs.

21 May 2026

First-of-its-kind pregnancy hormone test reveals why female IBD patients face severe symptom flares

Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn's disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated.

21 May 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Researchers identity patients with exceptional tirzepatide response outcomes

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally.

19 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Obesity drugs and surgery linked to greater fat-free mass loss

A new systematic review and meta-analysis of studies presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that diet and exercise interventions result in a lower proportion of fat-free mass loss compared with obesity surgery or obesity drugs among people undergoing a weight loss of 10% or more.

13 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Adding GLP-1 drugs to behavioral interventions silences food noise

New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs alongside behavioral interventions leads to a larger drop in so called 'food noise' than in those using the behavioral therapy alone.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Cannabis compounds may improve metabolism and reduce diabetes risk

A University of California, Riverside preclinical study is shedding light on a long-observed but poorly understood phenomenon: chronic cannabis users tend to have lower body weight and a reduced risk of developing type 2 diabetes, despite the drug's well-known tendency to increase appetite.

11 May 2026

New obesity drugs may shift blame toward food industry

An essay presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) suggests that new age of obesity drugs could shift the blame for living with obesity from individuals to the food industry – just as smoking has been blamed on tobacco industry and to a lesser extent alcohol consumption on the alcohol industry.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026